Use of Renin-Angiotensin System Blockers During the COVID-19 Pandemic: Early Guidance and Evolving Evidence.
作者信息
Turgeon Ricky D, Zieroth Shelley, Bewick David, Chow Chi-Ming, Clarke Brian, Cowan Simone, Fordyce Christopher B, Fournier Anne, Gin Kenneth, Gupta Anil, Hardiman Sean, Jackson Simon, Lau Benny, Leong-Poi Howard, Mansour Samer, Marelli Ariane, Quraishi Ata Rehman, Roifman Idan, Ruel Marc, Sapp John, Singh Gurmeet, Small Gary, Virani Sean, Wood David A, Krahn Andrew
机构信息
Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
University of Manitoba, Winnipeg, Manitoba, Canada.
出版信息
Can J Cardiol. 2020 Aug;36(8):1180-1182. doi: 10.1016/j.cjca.2020.05.033. Epub 2020 Jun 2.
Abstract
摘要
相似文献
1
Use of Renin-Angiotensin System Blockers During the COVID-19 Pandemic: Early Guidance and Evolving Evidence.2019冠状病毒病大流行期间肾素-血管紧张素系统阻滞剂的使用：早期指南及不断演变的证据
Can J Cardiol. 2020 Aug;36(8):1180-1182. doi: 10.1016/j.cjca.2020.05.033. Epub 2020 Jun 2.
2
The interplay of hypertension, ACE-2 and SARS-CoV-2: Emerging data as the "Ariadne's thread" for the "labyrinth" of COVID-19.高血压、血管紧张素转换酶2（ACE-2）与严重急性呼吸综合征冠状病毒2（SARS-CoV-2）之间的相互作用：新出现的数据成为2019冠状病毒病（COVID-19）“迷宫”中的“阿里阿德涅之线” 。
Hellenic J Cardiol. 2020 Jan-Feb;61(1):31-33. doi: 10.1016/j.hjc.2020.05.003. Epub 2020 May 22.
3
COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure.心力衰竭背景下COVID-19对肾素-血管紧张素系统的干扰
mBio. 2020 May 22;11(3):e00946-20. doi: 10.1128/mBio.00946-20.
4
Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know?肾素-血管紧张素系统与严重急性呼吸综合征冠状病毒 2 感染的相关性：我们了解多少？
Eur J Pharmacol. 2020 Sep 15;883:173373. doi: 10.1016/j.ejphar.2020.173373. Epub 2020 Jul 15.
5
Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System: JACC Review Topic of the Week.SARS-CoV-2 与肾素血管紧张素系统相互作用的临床意义：美国心脏病学会评论专题周报。
J Am Coll Cardiol. 2020 Jun 23;75(24):3085-3095. doi: 10.1016/j.jacc.2020.04.028. Epub 2020 Apr 16.
6
Can beta-adrenergic blockers be used in the treatment of COVID-19?β-肾上腺素能阻滞剂可用于治疗新型冠状病毒肺炎吗？
Med Hypotheses. 2020 Sep;142:109809. doi: 10.1016/j.mehy.2020.109809. Epub 2020 May 5.
7
ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective.ACE2（血管紧张素转化酶 2）、COVID-19 以及大流行期间 ACE 抑制剂和血管紧张素 II（血管紧张素 II）受体阻滞剂的使用：儿科观点。
Hypertension. 2020 Jul;76(1):16-22. doi: 10.1161/HYPERTENSIONAHA.120.15291. Epub 2020 May 5.
8
Renin-angiotensin system and SARS-CoV-2 interaction: underlying mechanisms and potential clinical implications.肾素-血管紧张素系统与新型冠状病毒2的相互作用：潜在机制及临床意义
Gen Physiol Biophys. 2020 May;39(3):203-204. doi: 10.4149/gpb_2020019.
9
Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers.肾素-血管紧张素系统阻滞剂与 COVID-19 大流行：目前尚无证据表明应放弃使用肾素-血管紧张素系统阻滞剂。
Hypertension. 2020 Jun;75(6):1382-1385. doi: 10.1161/HYPERTENSIONAHA.120.15082. Epub 2020 Mar 25.
10
SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.SARS-CoV-2 大流行和研究空白：了解 SARS-CoV-2 与 ACE2 受体的相互作用及其对治疗的影响。
Theranostics. 2020 Jun 12;10(16):7448-7464. doi: 10.7150/thno.48076. eCollection 2020.
引用本文的文献
1
The Impact of COVID-19 on Patients With ADPKD.2019年冠状病毒病对常染色体显性多囊肾病患者的影响
Can J Kidney Health Dis. 2021 Nov 10;8:20543581211056479. doi: 10.1177/20543581211056479. eCollection 2021.
2
Regulation of Angiotensin-Converting Enzyme 2: A Potential Target to Prevent COVID-19?血管紧张素转换酶 2 的调节：预防 COVID-19 的潜在靶点？
Front Endocrinol (Lausanne). 2021 Oct 22;12:725967. doi: 10.3389/fendo.2021.725967. eCollection 2021.
3
Randomized Prospective Open Label Study Shows No Impact on Clinical Outcome of Adding Losartan to Hospitalized COVID-19 Patients with Mild Hypoxemia.随机前瞻性开放标签研究表明，对轻度低氧血症的住院COVID-19患者加用氯沙坦对临床结局无影响。
Infect Dis Ther. 2021 Sep;10(3):1323-1330. doi: 10.1007/s40121-021-00453-3. Epub 2021 May 11.
本文引用的文献
1
Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19).血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂的使用与新型冠状病毒病 2019（COVID-19）检测阳性的关联。
JAMA Cardiol. 2020 Sep 1;5(9):1020-1026. doi: 10.1001/jamacardio.2020.1855.
2
Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults: A Living Systematic Review.血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对成人 SARS-CoV-2 感染的风险和影响：一项实时系统评价。
Ann Intern Med. 2020 Aug 4;173(3):195-203. doi: 10.7326/M20-1515. Epub 2020 May 15.
3
Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study.血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂与 COVID-19 住院风险的相关性：一项基于病例的队列研究
Lancet. 2020 May 30;395(10238):1705-1714. doi: 10.1016/S0140-6736(20)31030-8. Epub 2020 May 14.
Zotero 插件